Clinical Trial Update: Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pazopanib for reducing bleeding in hereditary hemorrhagic telangiectasia; the study was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Telangiectasia, Hereditary Hemorrhagic | Phase 2 | Status: TERMINATED | Results posted: 2017-07-06